Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Praxis Precision Medicines, Inc. - Common Stock (NQ:PRAX)

39.50 -0.20 (-0.50%)
Streaming Delayed Price Updated: 11:23 AM EDT, May 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Praxis Precision Medicines, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial Results
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Present at Truist Securities BioPharma Symposium
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Where Praxis Precision Medicine Stands With Analysts
Via Benzinga
What 5 Analyst Ratings Have To Say About Praxis Precision Medicine
Via Benzinga
Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines To Host Hybrid R&D Day on Monday, October 2, 2023
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For September 19, 2023
Via Benzinga
Recap: Praxis Precision Medicine Q1 Earnings
Via Benzinga
Praxis Precision Medicines to Present at H.C. Wainwright 25th Annual Global Investment Conference
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Present Data from Epilepsy Portfolio at the 35th International Epilepsy Congress
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Present Analyses of Patient-Focused, Clinically Meaningful Endpoints from Essential1 Study of Ulixacaltamide in Essential Tremor at the 2023 MDS International Congress
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Top 5 Health Care Stocks That May Fall Off A Cliff
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2023 Financial Results
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines Announces Positive Data from Randomized Withdrawal Sub-Study and Long-Term Extension of Essential1 Study for Ulixacaltamide
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
FDA's Rejection of Sage/Biogen's Zuranolone Boosts Prospects for Axsome's Auvelity, Analyst Says
Axsome Therapeutics Inc (NASDAQ: AXSM) reported Q2 sales of $46.7 million, beating the consensus of $40.19 million.  
Via Benzinga
Praxis Precision Medicines Announces Positive Results of EEG Analysis of PRAX-628 Phase 1 Study
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Participate at the 2023 Wedbush PacGrow Healthcare Conference
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines Announces Closing of Financing and Reiterates Corporate Priorities
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines, Inc. Announces Pricing of $59.1 Million Public Offering
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines Announces Plans to Begin Ulixacaltamide Phase 3 in Essential Tremor by Year End After Completing End of Phase 2 Meeting with FDA
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 2, 2023
Via Benzinga
Praxis Precision Medicines to Present at the 2023 Jefferies Healthcare Conference
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines Says PRAX-628 Can Potentially Be The Best-In-Class Treatment For Focal Epilepsy
Praxis Precision Medicines Inc (NASDAQ: PRAX) announced topline results from the PRAX-628 Phase 1 healthy volunteer study evaluating single ascending doses (SAD) and  
Via Benzinga
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2023 Financial Results
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines Announces Positive Topline Results from PRAX-628 Phase 1 Study Enabling Best-in-Class Profile
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Present at the American Academy of Neurology 2023 Annual Meeting
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines Announces Upcoming Ulixacaltamide Presentations & Events
Ulixacaltamide essential tremor end-of-phase 2 meeting with FDA scheduled for June 2023 
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.